Cytotoxic properties of aDEPTOR-mTORInhibitor in multiple myeloma cells

Cancer Research

Volumn 76, Issue 19, 2016, Pages 5822-5831

  Shi, Yijiang ^a   Daniels Wells, Tracy R ^a   Frost, Patrick ^a   Lee, Jihye ^a   Finn, Richard S ^a   Bardeleben, Carolyne ^a   Penichet, Manuel L ^a   Jung, Michael E ^a   Gera, Joseph ^a   Lichtenstein, Alan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIM PROTEIN; BINDING PROTEIN; DEPTOR PROTEIN; INSULIN RECEPTOR SUBSTRATE 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; NSC 126405; PROTEIN KINASE B; PROTEIN P21; UNCLASSIFIED DRUG; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DEPTOR PROTEIN, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MTOR PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; PROTEIN BCL 2; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SPECIFICITY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MOUSE; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SURFACE PLASMON RESONANCE; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MICE; MULTIPLE MYELOMA; MULTIPROTEIN COMPLEXES; PROTO-ONCOGENE PROTEINS C-BCL-2; TOR SERINE-THREONINE KINASES;

EID: 84989954121     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-1019     Document Type: Article

References (32)

1. Peterson T, Laplante M, Thoreen C, Sancak Y, Kang S, Kuehl WM, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009;137:1-14.
2. Duan S, Skaar J, Kuchay S, Toschi A, Kanarek N, Ben-Neriah Y, et al. mTOR generates an auto-amplification loop by triggering the beta TrCP- and CK1alpha-dependent degradation of DEPTOR. Mol Cell 2011;44:317-24
3. Gao D, Inuzuka H, Tan M, Fukushima H, Locasale JW, Liu P, et al. mTOR drives its own activation via SCFbTrCP-dependent degradation of the mTOR inhibitor DEPTOR. Mol Cell 2011;44:290-303.
4. Luo Z, Yu G, Lee H, Li L, Wang L, Yang D, et al. The Nedd8-activating enzyme inhibitorMLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Cancer Res 2012;72:3360-71.
5. Yang Y, Bardeleben C, Frost P, Hoang B, Shi Y, Finn R, et al. DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma cells. Genes Cancer 2014;5:407-19
6. Shi Y, Hsu JH, Hu L, Gera J, Lichtenstein A. Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of myeloma tumor cells to IL-6. J Biol Chem 200; 2277:15712-20.
7. Urashima M, Teoh G, Chauhan D, Hoshi Y, Ogata A, Treon SP, et al. IL-6 overcomes p21 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in myeloma cells. Blood 1997;90:279-89.
8. Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Lee K, Boise L. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907-16.
9. Rizziere D, Feldman E, DiPersio J. A phase 2 clinical trial of deforolimus, a novel mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2008;14:2756-62.
10. Huang J.An in vitro assay for the kinase activity of mTOR complex 2. Methods Mol Biol 2012;821:75-86.
11. Yoo EM, Trinh K, Tran D. Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma. J Interferon Cytokine Res 2015;35: 281-91.
12. Shi Y, Reiman T, Li W, Maxwell CA, Sen S, Pilarski L, et al. Targeting aurora kinases as therapy in multiple myeloma. Blood 2007;109:3915-21.
13. Chu H, Pazgier M, Jung G, Nuccio S-P, Castillo P, de Jong M, et al. Human alpha-defensin promotes mucosal innate immunity through self-assembled peptide nanonets. Science 2012;337: 477-81.
14. Annunziata CM, Hernandez L, Davis RE, Zingone A, Lamy L, Lam LT, et al. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood 2011;117: 2396-404.
15. Yen C, Lu Y, Li C, Lee C-M, Chen C-Y, Cheng M-Y, et al. Functional characterization of glycine N-methyltransferase and its interactive protein DEPDC6/DEPTOR in hepatocellular carcinoma. Mol Med 2012; 18:286-96.
16. Klionsky DJ, Abeliovich H, Agostinis P. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryocytes. Autophagy 2008;4:151-75.
17. Morales A, Kurtoglu M, Matulis S, Liu J, Siefker D, Gutman D, et al. Distribution of BIM determines MCL-1 dependence or codependence with BCL-XL/BCL-2 in MCL-1-expressing myeloma cells. Blood 2011;118: 1329-39.
18. Chen S, Zhang Y, Zhou L, Leng Y, Lin H, Kmieciak M, et al. A BIMtargeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood 2014;124:2687697.
19. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007;450:1001-9.
20. Jin L, Wang W, Fang G. Targeting protein-protein interaction by small molecules. Annu Rev Pharmacol Toxicol 2014;54:435-56
21. Sheng C, Dong G, Miao Z, Zhang W, Wang W. State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors. Chem Soc Rev 2015;44:8238-59.
22. Daw M, Chittajallu R, Bortolotto Z, Dev K, Duprat F, Henley J, et al. PDZ proteins interacting with C-terminal GluR2/3 are involved in a PKCdependent regulation of AMPA receptors at hippocampal synapses. Neuron 2000;28:873-86
23. Fujii N, You L, Xu Z, Uematsu K, Shan J, He B, et al. An antagonist of disheveled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res 2007;67:573-9.
24. Riz I, Hawley TS, Hawley RG. KLF4-SQSTM1/p62-associated pro-survival autophagy contributes to carfilzamib resistance in multiple myeloma models. Oncotarget 2015;6:17814-831
25. Malek MA, Jagannathan S, Malek E. Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma. Oncotarget 2015;6:3098-110.
26. Chen R, Yang Q, Lee J-D. BMK1 kinase suppresses epithelial-mesenchymal transition through the AKT/GSK signaling pathway. Cancer Res 2012;72: 1579-87.
27. Liu M, Wilk S, Wang A, Zhou L, Wang R-H, Ogawa W, et al. Resveratrol inhibitsmTORsignaling by promoting the interaction between mTOR and DEPTOR. J Biol Chem 2010;285:36387-94.
28. Cirstea D, Santo L, Hideshima T, Eda H, Mishima Y, Nemani N, et al. Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma. Mol Cancer Ther 2014;13:2489-500.
29. Mimura N, Hideshima T, Shimomura T, Suzuki R, Ohguchi H, Rizq O, et al. Selective and potent AKT inhibition triggers anti-myeloma activities and enhances fatal ER stress induced by proteasome inhibition. Cancer Res 2014;74:4458-69.
30. Kato H, Nakajima S, Saito Y, Takahashi S, Katoh R, Kitamura M. mTORC1 serves ER stress-triggered apoptosis via selective activation of the IRE1-JNK pathway. Cell Death Diff 2012;19:310-20.
31. Astle MV, Hannan KM, Ng PY, Lee RS, George AJ, Hsu AK, et al. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. Oncogene 2012;31:1949-62.
32. Desantis A, Bruno T, Catena V, DeNicola F, Goeman F, Iezzi S, et al. Che-1- induced inhibition of mTOR pathway enables stress-induced autophagy. EMBO J 2015;34:1214-30.